| Document |
Document Title |
|
WO2002030860A9 |
The present invention relates to novel ketone compounds, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders c...
|
|
WO/2003/013420A2 |
A non-toxic biologically active compound is provided having the following general formula (I), wherein n is an integer from 1 to 14, preferably from 2 to 4, and R is an organic moiety, preferably a group different from but structurally s...
|
|
WO/2003/009807A2 |
Cytoprotective compounds, many of which are phenolic derivatives characterized by a substituded phenol having certain conjugated bonds, are useful in the treatment of certain ischemic or inflammatory conditions, including but not limited...
|
|
WO/2003/007933A1 |
Provided are napthoquinone-type compounds which can be used to modulate the aggregation of protein (e.g. tau) associated with neurodegenerative disease (e.g. Alzheimer's disease). Structure-function characteristics for oxidised and reduc...
|
|
WO/2002/090304A1 |
By maintaining reduced coenzyme Q, which has not been employed in practice so far because of being liable to undergo oxidation and hydrophobic, stable against oxidation, a composition of a practically usable solution of reduced coenzyme ...
|
|
WO/2002/076939A2 |
Compounds having quinone and quinone analogs useful for pharmaceutical preparations have now been found which inhibit cysteine proteases, in particular, caspases and 3C-cysteine proteases. The cysteine protease inhibitors of the present ...
|
|
WO/2002/076916A1 |
A method of scavenging oxygen in an atmosphere or liquid comprising the steps of: (i) treating an anthraquinone compound according to the formula: (I) wherein X1-X4 and R1-R4 are as defined in the claims, with predetermined conditions so...
|
|
WO/2002/074800A1 |
This invention relates to the gene cluster for angucycline biosynthesis, derived from Streptomyces, and use of the genes therein to obtain antibiotics for drug screening.
|
|
WO/2002/050007A2 |
The present invention relates to stilbene and quinone compounds related to combretastatin A-4 and their use as anticancer compounds and prodrugs. The compounds include those with an alkyl group on the double bond of cis or trans-stilbene...
|
|
WO/2002/029014A2 |
Provided is a stem-cell differentiation and induction promoter, which comprises as an effective ingredient a cyclohexenone long-chain alcoholic derivative represented by the formula (1):[wherein, R?1¿, R?2¿ and R?3¿ each independently...
|
|
WO/2002/028808A1 |
This invention provides analogs of triptycene which are useful as anticancer drugs, as well as for other uses. The potency of these compounds is in a similar magnitude as daunomycin, a currently used anticancer drug. Each compound of the...
|
|
WO/2002/014530A1 |
The present invention provides a convergent method for the synthesis of ubiquinones and ubiquinone analogues. Also provided are precursors of ubiquinones and their analogues that are useful in the methods of the invention.
|
|
WO/2002/011563A1 |
A food supplement having prophylactic and-cancer effects, wherein the supplement comprises 20 to 99.99 % by weight of a product of biosynthesis by the productive microorganism Penicillium oxalicum var. Armeniaca CCM 8242, obtained by fer...
|
|
WO/2002/012218A1 |
The present invention is based in part on the surprising discovery that Tanshinones from Salvia miltiorrhiza act as allosteric high-potency N-methyl-D-aspartate receptor antagonists. Pharmacological blockade of excessive activation of N-...
|
|
WO/2002/012158A2 |
The invention relates to a method for catalytically producing organic substances by partial oxidation which is carried out in the gaseous phase in the presence of molecular oxygen at temperatures in the range of from 200 to 500 °C in at...
|
|
WO/2002/006261A1 |
The invention relates to the use of at least one component of formula (I) wherein R?1¿, R?2¿, R?3¿ and R?4¿ independently represent H or C¿1?-C¿6? alkyl. The invention also relates to the use of a compound of formula (I) for medica...
|
|
WO/2001/077052A1 |
Improved oxidation methods are provided wherein a reaction mixture comprising a substrate to be oxidized (e.g., phenols, alkenes) and an oxidation catalyst (typically dispersed in an organic solvent system) is supplemented with a compres...
|
|
WO2000039064A9 |
New compounds of formula (I) are described, wherein n is > 1; X is O or NR4; L is a n-valent linking group defined in claim 1 and R1 is H, halogen, C1-C25-alkyl, C3-C25-alkenyl, unsubstituted or by C1-C4-alkyl substituted C5-C8-cycloalky...
|
|
WO/2001/078162A2 |
OLED materials are provided that have the general formula: R?1¿-(Ar?i¿)¿n?-R?2¿ wherein the subscript n is an integer of from 5 to 15; the superscript i is an integer of from 1 to n and denotes the position downstream from R?1¿; eac...
|
|
WO/2001/068579A1 |
The invention relates to a method for producing 1,1' binaphthalenylidene-4,4'-diones of general formula (I), wherein R?1¿ represents C¿1-6? alkyl, C¿1-6? alkoxy, phenyl, substituted phenyl, benzyl or benzyloxy; R?2¿, R?3¿, R?4¿, an...
|
|
WO/2001/054730A1 |
The invention relates to a method for producing a coenzyme Q10 / $g(g)-cyclodextrin complex. Said method is characterized in that a mixture of $g(g)-cyclodextrin and coenzyme Q10 is treated by homogenisation and inputting energy.
|
|
WO/2001/046125A2 |
Substituted phenantheren-9, 10-diones in accord with structural diagram (I), compositions thereof and methods for the use thereof, for the treatment of T cell mediated conditions such as autoimmune diseases and organ graft rejection. In ...
|
|
WO/2001/045681A2 |
Substituted naphthalenediones in accord with structural diagram (I): compositions thereof and methods for the use thereof, for the treatment of T cell mediated conditions such as autoimmune diseases and organ graft rejection. In compound...
|
|
WO/2001/042243A2 |
Disclosed are compounds which inhibit or modulate the activity of protein kinases and pharmaceutical compositions containing such compounds. The disclosed compound contain two or more ligand moieties covalently linked together by one or ...
|
|
WO/2001/026482A1 |
A composition, preferably used to reduce methane formation in a ruminant, wherein the composition is a combination of a polycyclic quinone compound and an ionophore compound.
|
|
WO/2001/000554A2 |
Naphthoquinone derivatives of Formula (1): wherein, R represents an OH group, methyl ether, ethyl ether or a similar ether; R1 represents a methyl, ethyl or similar aliphatic hydrocarbon derivative; R2 and R3 each independently represent...
|
|
WO/2000/066528A2 |
Novel quinones are provided, as well as compositions comprising these novel quinones. Methods of using the novel quinones in treatment of various indications including cancer are also provided.
|
|
WO/2000/053655A1 |
The invention relates to conjugated polymers which contain triptycene units. According to the invention, the polymers are homopolymers made up of a repeating unit which contains a triptycenyl radical and copolymers made up of two or more...
|
|
WO/2000/023377A1 |
The invention concerns a novel method for preparing MEL-type titanium silicalite, the resulting product and its different uses in the field of catalysis. The inventive method for preparing MEL-type titanium silicalite is characterised in...
|
|
WO/2000/008495A2 |
The present invention provides a compound selected from the group consisting of (I), (II), and (III), wherein R?1¿ and R?4¿ are the same or different and are each H, C¿1?-C¿3? alkyl, phosphate, or C¿1?-C¿3? alkyl carboxylate; R?2¿...
|
|
WO/2000/002455A1 |
Hypericin has been shown to specifically inhibit T-type calcium channel activity. $i(Hypericum) extract containing hypericin also inhibits T-type calcium channel activity. Moreover, other chemicals in $i(Hypericum) extract showed a syner...
|
|
WO/1999/061409A1 |
A compound which consists of a proactive alkylating moiety containing an electron-withdrawing group, a bioreductive moiety containing at least two double bonds, and a linker joining the proactive alkylating moiety and the bioreductive mo...
|
|
WO/1999/052819A1 |
The invention relates to the anthraquinone cycle for producing hydrogen peroxide using at least two differently substituted 2-alkylanthraquinones and/or their tetrahydro derivatives. According to the inventive method, the working solutio...
|
|
WO/1999/050434A1 |
The strain of the microorganism Penicillium oxalicum var. Armeniaca CCM 8242 produces an anthraquinonyl carboxylic acid derivative of structural formula (I), which may be used as a colorant, especially as a food colorant or cosmetic colo...
|
|
WO/1999/048491A1 |
NF-$g(k)B inhibitors containing as the active ingredient benzoquinone derivatives represented by general formula (I), hydroquinone compounds thereof or salts of the same, wherein R¿1?, R¿2? and R¿3? independently represent each H, C¿...
|
|
WO/1999/041220A1 |
The invention relates to new hyperforin and adhyperforin salts, methods for producing same and their use. The cation of said salts is either an alkali metal ion or an ammonia ion of a salt-forming nitrogenous base, which salt-forming nit...
|
|
WO/1999/006347A1 |
Use of 1,3,4,6-tetrahydroxy-helianthrone and substituted derivative thereof as photoactivators for the photodynamic therapy of tumors. There are also provided novel substituted derivatives of 1,2,4,6-tetrahydroxy-helianthrone.
|
|
WO/1998/039337A1 |
Process for synthesising pure enantiomer anthracycline. Compounds of formula (I) can be produced by using compounds of formulas (II) and (III).
|
|
WO/1998/033757A1 |
The invention concerns a novel method for preparing substituted anthraquinone represented by the general formula (I) in which R represents a hydrogen atom or a linear or branched alkyl group of 1 to 5 carbon atoms, a chloromethyl group, ...
|
|
WO/1998/033758A1 |
A compound of formula (I), wherein R?1� and R?2� each represents a lower alkyl, or R?1� and R?2� may be bonded together to form a ring; X represents a spacer of which the number of atoms constituting the principal chain is 1 to 1...
|
|
WO/1998/023689A1 |
This invention relates to new blue anthraquinone colorants having Formula (I) wherein R and R�1? are the same or different and are selected from hydrogen and unsubstituted or substituted C1-C6 alkyl, C3-C7 cycloalkyl 2-furyl, 2-thienyl...
|
|
WO/1998/012313A1 |
A transformant prepared by constructing a plasmid wherein a human-inducible nitric oxide synthase (hiNOS) structural gene has been substituted by a luciferase structural gene which is a reporter gene while sustaining the functions of the...
|
|
WO/1998/008522A1 |
Multivitamin products targeted to specific groups.
|
|
WO/1997/031936A2 |
A novel synthetic method, novel compounds formed using the synthetic method, and uses for the compounds so made are described. The synthetic method results in the formation of o-naphthoquinone derivatives. These compounds find use as pot...
|
|
WO/1997/021684A1 |
The therapeutical use of tricyclic derivatives and pharmaceutically acceptable salts thereof having general formula (I), for treating diseases related to venous function deficiency and/or inflammatory oedema, is disclosed. In general for...
|
|
WO/1997/016404A1 |
A novel method for preparing substituted anthraquinones of general formula (I), wherein R is hydrogen atom or a straight or branched C1-5 alkyl group, a chloromethyl group, a -COCl group, a -COOR' group or a -CH2OR' group where R' is a h...
|
|
WO/1997/008262A2 |
This invention provides an aggregate of a compound capable of forming helical structures such that the aggregate is capable of achieving a specific rotation of at least 100,000� for plane polarized light having a wavelength of 589 nm.
|
|
WO/1997/003940A1 |
The present invention relates to a novel 6-substituted-5,8-dioxy-1,4-naphthoquinone derivative having formula (I), which is useful as an anticancer agent. In said formula, R1 represents alkyl; R2 represents hydrogen, alkyl or acyl; and R...
|
|
WO/1997/002271A1 |
This invention relates to certain naphthoquinone derivatives of general formula (1) or a salt thereof, in which m, n, R, R1, R2, R3, R4, R5, R6, R7, R8 are as defined in the description; processes for their preparation; compositions cont...
|
|
WO/1997/000675A1 |
The use of the compounds of formula (I), wherein the groups are as defined in the disclosure, for the preparation of medicaments for the treatment of pathologies in which the erosion of the cartilaginous and bone matrix occurs.
|
